全文获取类型
收费全文 | 13711篇 |
免费 | 1725篇 |
国内免费 | 329篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 141篇 |
妇产科学 | 94篇 |
基础医学 | 550篇 |
口腔科学 | 153篇 |
临床医学 | 2098篇 |
内科学 | 1223篇 |
皮肤病学 | 277篇 |
神经病学 | 550篇 |
特种医学 | 439篇 |
外国民族医学 | 9篇 |
外科学 | 750篇 |
综合类 | 2286篇 |
预防医学 | 1367篇 |
眼科学 | 187篇 |
药学 | 3107篇 |
70篇 | |
中国医学 | 1555篇 |
肿瘤学 | 860篇 |
出版年
2024年 | 93篇 |
2023年 | 334篇 |
2022年 | 633篇 |
2021年 | 953篇 |
2020年 | 996篇 |
2019年 | 634篇 |
2018年 | 579篇 |
2017年 | 785篇 |
2016年 | 762篇 |
2015年 | 623篇 |
2014年 | 1496篇 |
2013年 | 1424篇 |
2012年 | 1057篇 |
2011年 | 885篇 |
2010年 | 749篇 |
2009年 | 562篇 |
2008年 | 441篇 |
2007年 | 441篇 |
2006年 | 403篇 |
2005年 | 371篇 |
2004年 | 272篇 |
2003年 | 247篇 |
2002年 | 169篇 |
2001年 | 151篇 |
2000年 | 121篇 |
1999年 | 87篇 |
1998年 | 83篇 |
1997年 | 48篇 |
1996年 | 50篇 |
1995年 | 50篇 |
1994年 | 39篇 |
1993年 | 28篇 |
1992年 | 30篇 |
1991年 | 25篇 |
1990年 | 23篇 |
1989年 | 16篇 |
1988年 | 16篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 18篇 |
1984年 | 9篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1973年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
蒙天才 《中国继续医学教育》2020,(14):159-160
目的研究左乙拉西坦治疗小儿癫痫的疗效以及对智力的影响。方法在本院2017年4月-2019年5月收治的小儿癫痫患儿中选取74例开展研究,按照随机数表法分两组观察组和对照组,观察组37例,对照组37例,对照组采用奥卡西平进行治疗,观察组采用左乙拉西坦进行治疗,对比观察组与对照组组的治疗总有效率和智力评分变化。结果观察组与对照组比较,观察组的治疗总有效率较高,智力评分明显较高,两项对比差异有统计学意义(P <0.05)。结论左乙拉西坦治疗小儿癫痫有较好的治疗效果,治疗总有效率较高,且对患儿的智力有明显的改善作用,在实际临床小儿癫痫的治疗中具有较高的运用价值。 相似文献
2.
Recognizing and managing a deteriorating patient: a randomized controlled trial investigating the effectiveness of clinical simulation in improving clinical performance in undergraduate nursing students 下载免费PDF全文
3.
4.
目的:探究桃红四物汤联合银杏酮酯滴丸治疗老年出血性玻璃体混浊的临床疗效。方法:收集2016年12月-2018年12月我院收治的老年出血性玻璃体混浊患者67例,共67眼,根据随机对照表分为对照组和试验组,其中试验组34例,对照组33例,对照组予以银杏酮酯滴丸;试验组在对照组的基础上联用桃红四物汤。两组均服用30 d。治疗结束后对比分析两组患者临床疗效、出血吸收时间、血液流变学及视网膜中央动脉血流动力学。结果:治疗后两组患者高切全血粘度、低切全血粘度、纤维蛋白原、阻力指数(Resistance Index,RI)低于治疗前,收缩期峰值速度(Peak Systolic Velocity,PSV)、舒张末期血流速度(End Diastolic Velocity,EDV)高于治疗前,差异具有统计学意义(P<0.05);治疗后试验组临床总有效率、PSV、EDV高于对照组,出血吸收时间、高切全血粘度、低切全血粘度、纤维蛋白原、RI低于对照组,差异具有统计学意义(P<0.05)。结论:桃红四物汤联合银杏酮酯滴丸治疗老年出血性玻璃体混浊临床疗效显著,适宜临床应用推广。 相似文献
5.
6.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
7.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
8.
湿润烧伤膏治疗褥疮26例的临床体会 总被引:7,自引:0,他引:7
目的:进一步观察湿润烧伤膏对治疗褥疮的疗效,寻找最理想的治疗方法。方法:通过对26 例不同原因所致褥疮的治疗,探索湿润烧伤膏对治疗褥疮病人最合理的用药方法,创面的变化及其愈合时间。结果:25例病人创面愈合,死亡1例。结论:湿润烧伤膏治疗褥疮方法简便,实用性强,疗效显著,值得各级医院推广。 相似文献
9.
AIMS: To compare long-term (1 year) efficacy and safety of pioglitazone and gliclazide in patients with Type 2 diabetes. METHODS: This was a double-blind, multicentre, comparative, parallel group trial in 283 patients with Type 2 diabetes, who were randomized to receive 1-year treatment with pioglitazone 30-45 mg/day or gliclazide 80-320 mg/day. Drug dose was titrated on the basis of self-monitored blood glucose (SMBG) measurements and HbA1c values. The 1-year changes in HbA1c, fasting blood glucose (FBG), insulin, HOMA-S (HOmeostatic Model Assessment) and SMBG were compared. In a subgroup of patients (n = 10), systemic glucose production and utilization were determined by a combination of isotopic (deuterated glucose) and clamp techniques. RESULTS: In both groups, there were similar decreases in HbA1c (pioglitazone: -0.79%; gliclazide: -0.79%) and FBG (pioglitazone: -1.0 mmol/l; gliclazide: -0.7 mmol/l), whereas the slope of the reduction of fasting blood glucose was different between groups (P = 0.004). Insulin levels as well as insulin resistance assessed using HOMA-S decreased significantly only after pioglitazone treatment (-11.94 pmol/l and -1.03, respectively, both P = 0.002 vs. baseline). A significantly greater reduction in systemic glucose production was observed in the pioglitazone group (-2.48 micromol/kg/min, P = 0.042) than in the gliclazide group (-1.02 micromol/kg/min). A few, mild adverse events occurred in both groups. CONCLUSIONS: A comparable decrease in HbA1c and FBG was observed with pioglitazone and gliclazide. However, with pioglitazone there was a continuous decrease in FBG over 1 year, whereas gliclazide failed to maintain a similar trend. This favourable effect of pioglitazone was due to its insulin-sensitizing effect and ability to decrease systemic glucose production. 相似文献
10.
杨永康 《中国烧伤创疡杂志》2006,18(3):223-225
目的:观察美宝湿润烧伤膏在血栓性外痔和陈旧性肛裂切除术后治疗中的疗效。方法:术毕用MEBO纱布条填塞伤口,术后24小时取出纱布条,以后用MEBO涂于伤口内,每日2次,直至痊愈。结果:48例患者无术后伤口疼痛、出血、感染及肛门狭窄。伤口愈合时间短,治愈率高。结论:美宝湿润烧伤膏是血栓性外痔、陈旧性肛裂切除术后良好的局部治疗药物。 相似文献